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INVITED TALKS
CHAIRMEN’S FOREWORD
Jerzy Jastrzębski and Leszek Królicki
On behalf of the Polish scientific community we have the privilege and pleasure to welcome you 
to Warsaw for the PETRAD2012 Conference. The Conference follows the opening of the University 
of Warsaw Radiopharmaceuticals Production and Research Centre. The main goal of this centre 
is the production of radioisotopes and radiopharmaceuticals for Positron Emission Tomography 
(PET) laboratories in Poland as well as research into new, innovative radiopharmaceuticals. 
Poland was terra incognita on the PET map of Europe for many years. This was due to a number 
of political and financial problems. The first PET Laboratory in Poland was opened at the Onco-
logical Centre in Bydgoszcz in 2003. The PET programme of the Ministry of Health, launched in 
2006 was the second milestone. At present there are 15 operational PET-CT cameras in Poland 
and some new ones will be installed shortly. These data firmly indicate that the method is ac-
cepted by doctors, scientific societies and the Polish national health service. The PETRAD2012 
Conference is certainly a good opportunity to celebrate our story; a story of a multidisciplinary 
approach to a challenging scientific and social activity. 
Every year new fields for PET in clinical and scientific applications are being opened. PET-
RAD2012 aims to summarize some of these possibilities. This is the first international PET 
conference to be held in Poland and its success will depend — above all — on the effort of our 
guests: invited speakers and authors of the oral and poster presentations Their knowledge and 
experience will certainly contribute to new ideas for all conference participants. In this Book of 
Abstracts this effort is only highlighted, you will learn more by participating in the Conference 
sessions and attending the Poster presentation. We hope that the publication of the Conference 
Proceedings at the end of this year will provide a permanent record and a good summary of 
this scientific event.
We thank all participants for visiting our Centre and selecting our Conference among so many 
other meetings all around the world. We do hope that your visit to Warsaw this time will not be 
your last and that our contacts, with the accompanying exchange of ideas and experience, will 
continue.
Last but not least, we address our deep thanks to the Sponsors of this Conference. Without 
their generous support the organization of this scientific event — unique in our region — would 
certainly not have been possible. 
Have a good time in Warsaw!
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THE RADIOPHARMACEUTICALS PRODUCTION AND RESEARCH 
CENTRE AT HIL UW
Jarosław Choiński
Heavy Ion Laboratory, University of Warsa w, Poland
The Heavy Ion Laboratory (HIL), University of Warsaw has recently gained a new capability, 
the Radiopharmaceuticals Production and Research Centre (RPRC). Opening in 1993, the HIL 
is an accelerator laboratory operating a Kmax = 160 heavy ion cyclotron currently equipped 
with two ECR ion sources: a homemade 10 GHz source with a classical magnetic trap, and 
a commercial Pantechnik 14 GHz Supernanogan source. Our main activity is focused on re-
search in nuclear physics, materials and solid state physics, atomic physics and the life scie-
nces. Our newly finished large project extends our interests to the production of classic PET 
radiopharmaceuticals and research into innovative radiopharmaceuticals, also including metallic 
targets. The aim is to establish a radiopharmaceutical production centre for Positron Emission 
Tomography in the Central part of Poland, mainly in Warsaw and the surrounding region. The 
one of the crucial conditions of the tender was that the project had to fulfill Good Manufacturing 
Practice requirements. In this presentation the author will give a short description of the history 
of the whole project, including of course the sponsoring Authorities and the close collaboration 
with the International Atomic Energy Agency under the contract “The provision of a cyclotron 
system, targets and equipment for the manufacture of 18F — Fluorodeoxyglucose and other 
radiopharmaceuticals for operation at the Heavy Ion Laboratory of the Warsaw University”. 
Finally, the remaining conditions and expectations included in the tender will be presented. 
Participants will become acquainted with the main equipment destined for the production of 
FDG, for R&D and QC activity.
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A LOOK AHEAD: PET/MR VERSUS PET/CT
Gustav K von Schulthess
Dept of Medical Radiology, University Hospital, Zürich, Switzerland
Over the past decade, the introduction of PET/CT has catapulted PET and particularly FDG 
PET from an interesting, but not to well understood imaging — into a diagnostic mainstream 
technology, which modern oncology considers standard very much as e-mail and the mobile 
phone have become the mainstay of communication. PET/CT was very much a technology, 
oncology was waiting for. Application of FDG-PET/CT has taught us many new insights on how 
to stage and monitor tumors. FDG activity seems to be an excellent predictor of patient sur-
vival and a lack of response of a tumor to therapy is almost always reflected in persisting FDG 
uptake. Some subtleties of PET scan interpretation have only been understood in combination 
with CT. Brown fat uptake, globular muscle uptake, benign entities showing FDG uptake such 
as Warthin’s tumor, were mostly unknown in the days of PET only. Hence, addition of CT to 
PET was dearly needed and made PET more sensitive and specific, resulting in a better test, 
demonstrating impact on management in up to 50% of cases examined. Use of FDG-PET/CT 
in the diagnosis and follow-up of inflammatory lesions also has been steadily increasing, while 
PET applications in the brain and heart, originally considered the key indications to perform 
PET scans, have not nearly seen a comparable surge in utilization.
Over the last several years, various groups have been experimenting with the integration of PET 
with MR and currently, the three major imaging equipment manufacturers offer three different 
versions of PET/MR systems. In complete contrast to PET/CT, no compelling clinical indica-
tions for PET/MR have been defined. PET/MR thus remains largely a technology looking for 
an application. Numerous interesting applications of PET/MR have been proposed and there 
is no question, that PET/MR is an extremely interesting research tool.
In order for a costly technology to establish itself in the clinical environment, at least one key 
clinical application has to be developed, where the technology is superior to all other technolo-
gies. This has been amply demonstrated by the initial success of MR in imaging brain disease 
and PET and PET/CT in oncology. The task for research groups disposing of PET/MR is thus to 
find such a “killer” application. However, various obstacles are in the way of a large scale in-
troduction of PET/MR.
Technology
Building a PET system which works in the magnetic field of an MR scanner is costly and the 
technology necessary is just developing. Solutions seem to be Avalanche Photodiode or Silicon 
Photomultiplier based detectors which can replace the unsuited standard photomultipliers as PET 
detector components. The use of MR data for attenuation correction is still far inferior to using 
CT data and standardized pulse sequences easily integrated in a PET whole body examination 
workflow are not clearly defined yet.
Clinical
The simultaneous data acquisition potentially possible with PET/MR is largely irrelevant clinically. 
Standard PET tracers used in clinical practice are injected and after a substantial wait time, the 
examination takes place. In this context it is not even clear, what the meaning of “simultane-
ous data acquisition” really is.
Oncology: while in principle MR has considerable advantages in head and neck, liver and pel-
vic imaging, it is not clear whether the combination with PET maintains this advantage, i.e. the 
fact that MR is better than CT does not automatically mean that PET/MR is better than PET/CT 
in a given application. Oncology requires a head to pelvic floor scan in most situations. Many 
tumors are prone to result in lung metastases. Hence, good lung imaging in such a partial 
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body procedure is critical. MR is substantially inferior to CT in lung imaging and this problem 
has to be solved. Some early data show that PET/MR > PET/CT in liver lesions, but otherwise 
data are sparse.
Neurology: brain imaging is potentially an interesting area for PET/MR because of the well 
known inferiority of CT compared to MR. However, current clinical PET indications in the brain 
are limited, and so clinical use is not foreseen to be dramatically altered by the introduction of 
PET/MR. This may well change when the PET plaque imaging agents become available in the 
next 2–3 years. Still, the only compelling reason to use integrated PET/MR is that the patient 
needs to undergo both examinations. Doing “two for one” thus shortens imaging time. PET/MR 
will be undoubtedly a very interesting brain imaging research tool.
Cardiology: PET perfusion and viability imaging have established themselves in the clinical 
environment, but SPECT perfusion and MR viability imaging are excellent alternatives. Again, 
compelling clinical indications for integrated PET/MR in the heart are not on the horizon. With 
the advent of PET-based perfusion tracers, potentially interesting combined clinical applica-
tions can be thought of and like in the brain, PET/MR is an interesting research tool. e.g. for 
cross-validation of MR- and Nuclear Techniques based perfusion imaging.
In summary, PET/MR — unlike PET/CT — is a technology looking for clinical applications. 
There is little doubt that some will emerge in the future. At this moment PET/MR is an extremely 
interesting research tool.
A5www.nmr.viamedica.pl
Invited talks Abstracts
PARTICLE ACCELERATORS FOR PET RADIONUCLIDES
Mikael Jensen 
DTU-NUTECH, Technical University of Denmark, Roskilde, Denmark
Radionuclides suitable for use in PET imaging will always be found very close to the line of 
stability in the chart of nuclides. The requirements of suitable half-life and almost pure positron 
emission lead to a few dozen widely used isotopes, that can all be made by (p, n) or (p, alpha) 
reactions by protons in the range of 5 to 11 MeV. Only the production of the short-lived physio-
logical tracer O-15 warrants the use of deuterons as alternative to protons.
Higher energy protons (in the range of 11–19 MeV) can be justified in terms of more robust target 
windows, thicker targets and higher yields, but the technological evolution of high current, low 
energy targets has lead  to very good performances even at 11 MeV.
Although various types of linear accelerators (electrostatic, Alvarez-type and RFQs) have been 
developed and successfully used for PET, they have never demonstrated superior performance 
or lower cost when weighted against the activity outputs of the universally accepted isotope 
production accelerator: the cyclotron. 
The energy range and the intensities needed for PET radionuclide production are extremely well 
covered by modern compact (also called medical) cyclotrons. Although the basic principle of 
the cyclotron is now more than 80 years old (Lawrence-1932), many developments during the 
last 30 years have made the cyclotrons much more reliable instruments. They are powerful in 
terms of isotope output, they are user friendly and easily serviced and with reasonably small 
requirements for space, power and cooling. 
With this said, there remains little reason to decide for anything else than cyclotron for PET 
radionuclide production, whether it is for routine clinical use or for research. However, there 
remain a lot detailed choices, not only on maximum beam energy between handfuls of well 
established commercial manufacturers, but also between different sizes and installations of the 
cyclotron: bunker versus self-shield, possible beam lines for solid targets or target multiplexing 
directly on the cyclotron tank.
The Atomic Energy Agency has recently issued a number of very useful guidelines to assist the 
right size of cyclotron and the design and operation of a PET radioisotope facility (IAEA, TRS 
references given below). These texts will guide the reader also to the very important interplay 
between the accelerator itself and the targets, the radiochemistry, the pharmaceutical and 
regulatory issues and the operational costs. 
The talk will highlight some of the key technical issues when deciding for a facility for PET ra-
dionuclide production. From many years of experience with the start up of new PET centres, the 
most important advice is first to plan the projected use of the cyclotron during the first 10–20 
years of operation (a cyclotron may well last for more than 40 years),- and then use this plan to 
choose the cyclotron. It is indeed possible to buy every feature and all possible targets for a new 
machine, but this is very rarely justified in terms of any practical use. Instead, it adds much to 
cost, space requirements and to the complexity of site planning, commissioning and operation. 
It is my personal experience, than no cyclotron has been too simple to be of any use in practical 
PET life. On the contrary, some machines have indeed been too sophisticated to make them 
reliably available for daily life in a PET environment. 
The talk will discuss the issues of beam energy, maximum target current, activity outputs and 
operational costs from the basis of the available technology. But it will also try to embrace some 
very promising current developments in terms of very compact “bed side” PET tracer delivery 
systems based on highly integrated small cyclotron systems. The advent of such platforms might 
once again change the way that we think and operate PET facilities in the future. 
The talk will also address the possible impact of the so-called Technetium Crisis on the both the 
choices and the economics of cyclotrons of higher energies, marginally useful for PET, as well 
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as the obvious disparity of scale and sophistication between conventional single photon emitter 
imaging and current PET imaging possibilities. 
As before, much of the evolution in nuclear medicine is driven by developments by the com-
munity of cyclotron engineers and target wizards. The very small machines that are only made 
possible by advances in cyclotron technology, target materials, radiochemistry systems and 
in software control may well make a much wider range of PET tracers clinically available on 
a broader scale and in larger numbers than previously believed possible.  
References
1. Lawrence EO. The Production of High Speed Light Ions Without the Use of High Voltages; Physi-
cal Review 1932; Vol. 40, Issue 1: 19–35, April 1
2. IAEA: Technical report Series 465 and 468 (Cyclotron produced radionuclides).
3. IAEA: Technical Report Series 471: (Cyclotron produced radionuclides: guidelines for setting 
up a facility).
A7www.nmr.viamedica.pl
Invited talks Abstracts
FROM TARGET TO SMALL-ANIMALS IMAGING
John C Clark
University of Edinburgh
Outline
1. Intro How to get PET radiopharmaceuticals into living systems? Main PET radionuclides used 
are 18F and 11C others much less widely used. Useful chemistry good imaging character-
istics why others less useful.
2. Evolution of 18F targetry
 Early H2
16O water targets for fluoride leading to present high current H2
18O18FDG factory 
targets.
3. Evolution of 11C targetry
 Solid targets of B2O3used in discovery experiments. Can be used with pr tons or deuterons. Recov-
ery of 11C can be problematical several methods developed before  theintroduction14N(p,alpha)11C 
gas targetry. Some significant  in-target chemistry will be described.
 How to convert the target output into a radiopharmaceutical?
 Fast synthetic organic Radiochemistry and it’s automation.
4.  Essentials characteristics include reaction vessels with heating and cooling made of com-
patible materials, valves and pipes with appropriate qualities for the media and pressures of 
the gases liquids and vapours, to be transported.
 Control of the process sequence including temperature control, reagent additions, reac-
tants mixing solvent evaporations etc.
 Early systems controlled using manual switches which were replaced by programmable 
controllers (PLC’s).More recently control has been achieved using computers (PC’s) with 
a variety of interface methodologies.
 Purification of the desired product from the crude reaction mixture using ion exchange or 
more solid phase extraction. Often based on analytical reverse phase HPLC with radioactivity 
and UV detectors situated at the column outlet.
 Formulation and terminal sterilisation. Often the HPLC solvent must be removed and ex-
changed for a more biologically appropriate one. Reverse phase cartridges often referred 
to as C 18 Sep Pak’s provide an effective solution.
To autoclave or not to autoclave?
5. Animal PET it’s roots and rapid growth
 Early attempts to build instruments from best available BGO block detectors  made for hu-
man scanners. CTI/Hammersmith collaboration on ”RATPET” with  low resolution but high 
sensitivity.
 CERN multiwire proportional counter detector technology re-engineered to provide whole 
body animal PET scanner Oxford PositronQuad HIDAC. High resolution but low sensitivity.
 LSO breakthrough yielding lots of very fast light allowing much small crystal elements to be 
made leading to sub millimetre intrinsic resolution.
 Multmodality PET/CT followed on from Human usage and PET/MR developed in various pro-
totype forms examples.
6. Animal PET problems and pitfalls. Examples illustrating some strengths and weaknesses.
7. Conclusion with a look into the future from a personal standpoint.
A8
Nuclear Medicine Review 2012, Vol. 15, supplement A
www.nmr.viamedica.pl
Abstracts
PRESENT AND FUTURE OF PET-RADIOPHARMACEUTICALS
Philip H Elsinga
University Medical Center Groningen, University of Groningen, The Netherlands
The selection of appropriate animal models, suitable validated tracers and kinetic analy-
sis are key issues for successful application of PET.
Although number of newly discovered biological targets (often of poorly understood function) 
is increasing rapidly, the repertoire of well-characterized PET radiotracers for in vivo imaging 
is limited. Therefore radiochemists will play a continuing crucial role in the discovery and 
development of PET radiopharmaceuticals to enable the study of novel biological targets and 
evaluate treatment in humans. Several criteria should be considered in the development 
of novel PET probes for in vivo imaging, such as choice of radionuclide, position of label-
ling, metabolism, non-specific binding and radiolabelling strategies. The development of 
new PET imaging probes relies mainly on 2 radionuclides. Carbon-11 is the radionuclide 
of choice for radiolabelling the investigational drug.  Replacement of naturally occurring 
carbon-12 by carbon-11 does not alter the (bio)chemical properties of a molecule. Since 11C 
can directly replace stable carbon in the compound of interest it is of the greatest interest 
to drug discovery and development. Many synthetic routes to 11C-compounds are already 
available and several others are still under development. Because of the very short radioac-
tive half life of 11C the synthetic procedures should be very efficient. The second radionuclide 
is fluorine-18, mainly due to its adequate physical and nuclear characteristics. There is still 
a need to simplify 18F-chemistry to allow better dissemination of PET which may become 
comparable to conventional SPECT.
Fluorine-18 is the most often used radionuclide for diagnostic PET imaging because physical 
properties of 18F are very favourable. Among the routinely produced very short-lived positron 
emitters, the relatively longer half-life of 18F poses less constraints on synthesis time and 
permits longer imaging protocols to investigate processes of slower tracer kinetics.
Currently, FDG is the most widely used (~90%) radiopharmaceutical in PET often making 
PET synonymous to a study using FDG. A large number of drugs and biomolecules have 
been evaluated for labeling with fluorine-18 in order to apply radiopharmaceuticals that 
target specific biochemical processes. Thanks to the continued efforts of a large number 
of scientists in several countries, there is now a wide variety of 18F-tracers that can be used 
for PET studies in the fields of oncology, inflammation, neurology, psychiatry, and cardio-
logy. However, these radiopharmaceuticals are not optimally used. Therefore it is of utmost 
importance to translate these radiopharmaceuticals into a clinical setting for the better 
understanding of the disease process in humans. 
The relatively longer half-life of 18F also permits the distribution of 18F-labelled radiopharma-
ceuticals to clinical services approachable within a few hours of transport. The initiatives of 
several small and medium companies made possible the regular supply of GMP grade 
18F-labelled radiopharmaceuticals from a single cyclotron/PET radiopharmaceutical produc-
tion facility to several clinical PET centers. ‘Cyclotron-PET satellite’ concept is a successful 
business venture in many parts of the world and significantly contributed to the growth in the 
number of PET/CT cameras installed all over the world. The market is still rapidly expanded 
also due to its exponential growth in developing countries.  
Centralized versus non-centralized radiopharmaceutical production holds several issues in 
relation to cost-effectiveness, regulations and scientific innovations. Besides aspects of 
regulation there is impact on the design of the facility and the required equipment. As a con-
sequence new synthesis equipment based on microfluidics is under development to produce 
PET-radiopharmaceutical s on patient basis.
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Finally metal-based PET-radionuclides such as 64Cu, 89Zr and 68Ga are increasingly used 
thereby building on the longlasting experience that the community gained with SPECT-radio-
pharmaceuticals. These radionuclides are mainly being used for radiolabelling of peptides, 
proteins and antibodies. Since 64Cu and 89Zr have a relatively long half life they may easily be 
distributed over long distances and can be used to produce a wide range of peptides and 
antibodies. 68Ga is available through a generator and is very suitable to produce radiolabelled 
peptides. The metal-based radionuclides have the advantage that they can be available 
without having the expensive cyclotron infrastructure.
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RECONSTRUCTION IN POSITRON EMISSION TOMOGRAPHY: 
2D-4D, RESOLUTION RECOVERY, ARTEFACT REDUCTION
Andrew Todd-Pokropek
University College London, London, UK
The basic problem to solve is the solution of the inverse problem P = F.X where P are the acquired 
data, F is the forward or system matrix and X are the image(s) to reconstruct and then quanti-
tate. Although direct methods such as Filtered back Projection exist, now iterative methods are 
almost always used. Both list mode where each line of response is considered individually, and 
methods where frames of projection images are formed. Associated problems include unifor-
mity correction (or normalisation of sensitivity), decay, scatter and randoms correction, and of 
course attenuation correction. Reconstruction is normally of volumes including currently semi 
whole body, and therefore motion correction, and redistribution of activity hence4-d reconstruc-
tion i.e. of 3-d data in time, as a function of a physiological time activity information. Note that 
the 3-d itself is a limited angle problem. The iterative solution of the inverse problem is typically 
using a method such as MLEM (or variants) where a guessed solution Xn uses F to generate 
a guessed set of projections Pn’ which are compared with P the original raw data to create 
modifications to Xn until a ‘satisfactory’ solution is found. This can be done in 2-d, 3-d or4-d. 
However note that problem is in principle quite large. How should F be represented? One useful 
tool is this process is Monte Carlo simulation but reasonable reconstruction times are required 
although the use Graphic Processor Units (GPUs) are now often used. F is often computed 
dynamically (on the fly), rather than precomputed and then stored. In the 4-d (time) problem 
a compartmental model can be assumed and the interactive solution includes a search for the 
coefficients of the model itself. 
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PET IN NEUROLOGICAL RESEARCH AND DIAGNOSTICS
Bernard Mazoyer
Groupe d’Imagerie Neurofonctionnelle, UMR5296CNRS, CEA, Université de Bordeaux
From its inception in the mid 70’s, PET has been a major tool for basic and clinical neuroscien-
tists. Today, PET continues toplay a critical role in preclinical fundamental research both for the 
understanding of brain disease pathophysiology and for drug development. But PET is also 
routinely used for the diagnostic and the theranostic of many neuropathologies, including major 
social impact brain diseases such as stroke, neurodegenerative disorders, including Alzheimer 
and Parkinson diseases, and epilepsy.
Tracing neurobiological processes with PET
Because of its intrinsic exquisite sensitivity, and thanks to the wide spectrum of high specificity 
available radiotracers, PET can indeed assess many neurophysiological and neuropathophysio-
logical processes in vivo. For instance, parameters of regional cerebral energy supply and 
consumption parameters can be quantitatively estimated, including blood flow (with 15O-water 
or 15O-butanol), glucose (with 18F-deoxyglucose or FDG) and oxygen metabolism (with 15O2, 
18F-misonidazole or FMISO) and used to evaluate neural cell degeneration. Similarly, brain pro-
tein synthesis and turnover can be locally measured with labeled amino acids (11C-Methionine, 
11C-Leucine, 18F-Tyrosine, α11C-Methyl-Tryptophan or AMT) or nucleoside (18F-Thymidine or FLT), 
allowing the assessment and follow-up of brain cell division. Even more interesting for research 
purposes, is the unique ability of PET to allow the investigation of brain neurotransmission sys-
tems. The regional distribution, kinetic parameters and metabolism of neurotransmitters and 
membrane receptors can so be quantified for the dopaminergic (11C-Raclopride, 18F-DOPA), 
serotoninergic (18F-Altanserin, 18F-CWAY), cholinergic, gabaergic-A central (11C-Flumazenil, 
FMZ), peripheral benzodiazepine (11C-PK1185), and opioid (11C-Carfentanyl) systems, to name 
the most important of them. For several brain disorders, such PET tracers are extremely use-
ful 1- for the understanding of their pathophysiology at the molecular level, thereby allowing 
the identification of specific therapeutic targets, and 2- for designing optimal PET diagnostic 
and theranostic tools. Last but not the least, PET is also the technique of choice for the evalu-
ation of b-amyloid aggregation and neuritic plaque formation (using 11C-PIB, 18F-florbetapir or 
18F-flutemetamol), two processes thought to be at the core of the pathophysiology of neurode-
generative disorders, including AD.
PET diagnostic and theranostic of neuropathologies
Alzheimer disease and other neurodegenerative disorders. This is the domain where PET 
is the most useful in both the research and clinical routine areas, one major pathology being 
extensively investigated with PET, namely Alzheimer disease (AD). AD, the most common cause 
of dementia and an important challenge for healthcare systems, is initially characterized by 
memory complaints, evolving later on towards severe cognitive decline. At the molecular/cellular 
level, AD is characterized by the presence of amyloid–β (Aβ) plaques, neurofibrillary tangles and 
activated microglia, resulting in neuronal cell loss. These neuropathological changes are thought 
to precede cognitive symptoms by many years, which justifies the use of PET using both FDG 
and Aβ markers (such as 11C-PIB or newly developed 18F-labeled tracers, see above) in order: 
1 — to make an early detection of the disease, 2 — to predict whether or not a subject with 
mild cognitive impairment (MCI) will end up having AD, 3 — to make differential diagnosis with 
other diseases such as Lewis body dementia or fronto-temporal dementia (FTD), 4 — to as-
sess treatment outcome. Other PET tracers, including for various neurotransmitter systems, are 
used to progress in the knowledge of AD pathophysiology.
Cerebrovascular disease (CVD). CVD results from an imbalance of the normal relationship 
between the cerebral vasculature and the brain parenchyma, sometimes resulting in stroke. 
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PET should be the technique of choice for investigating stroke, being the only technique able 
to provide quantitative and reliable estimates of cerebral blood flow (H2
15O), blood volume 
(C15O), and oxygen (15O2) and glucose (FDG) metabolisms. However quantitation and the use 
of short-lived positron emitters (123 sec for 15O) makes its use restricted to the preclinical or 
clinical research area. Nevertheless, PET has been found to be invaluable for the understan-
ding of the compensatory responses of the brain to reductions in perfusion pressure and their 
associated changes in blood flow and metabolism, paving the way for the design of new treat-
ment strategies.
Epilepsy. Epilepsy is a chronic disorder characterized by recurrent and unprovoked seizures. 
Epilepsy is controlled with drugs in 70% of the cases. When seizures cannot be controlled, 
surgery is considered and interictal PET with FDG is used to localize the seizure onset zone to 
be resected. In preclinical research GABAA opioid, and serotoninergic neurotransmission are 
being investigated with PET as existing or possible therapeutic targets.
References
1. Goffin K, Dedeurwaerdre S, Van Laere K, Van Paesschen W. Neuronuclearassessment of patients 
withepilepsy. Semin Nucl Med 2008; 38: 227–239.
2. Jagust WJ. Amyloidimaging. Arch Neurol 2011; 68: 1377–1378.
3. Nordberg A, Rinne JO, Kadir A, Langström B. The use of PET in Alzheimer disease. Nat Rev 
Neurol 2010; 6: 78–87.
4. Powers WJ, Zazulia AR. PET in cerebrovasculardisease. PET Clin 2010; 5: 1–37.
5. Vallabhajosula S , Vallabhajosula B. A broadoverview of positron emissiontomographyradiophar-
maceuticals and clinical applications: what is new? Semin Nucl Med 2011; 41: 246–264.
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RADIONUCLIDE-BASED REPORTER GENE IMAGING: 
CLINICAL IMPLEMENTATION AND APPLICATION
Ronald Blasberg
Memorial Sloan-Kettering Cancer Center, New York, USA
“Pre-targeting” (delivery) of a reporter gene to the target tissue by transfection or transduction 
is a requirement for all reporter gene imaging studies. The reporter gene construct usually 
includes transcriptional control elements that can initiate and regulate reporter gene expres-
sion. Two general groups of promoter-enhancer control elements are recognized; one group 
comprises “constitutive” promoters that result in continuous expression of the reporter gene; 
the “always on” motif. The other group comprises “inducible” promoters that are activated by 
endogenous transcription factors that function as a specific cellular “switch”.
“Constitutive” driven reporters can be used to identify the site, extent and duration of vector de-
livery, and can be used to monitor the efficiency of tissue and cell transduction (the normalizing 
term) for subsequent image and data analysis. “Constitutive” driven reporters can also be used 
to “label” specific cells, and this can be performed ex vivo as well as in vivo. For example, the 
long-term monitoring of T cell trafficking and localization is well recognized as an important com-
ponent in studies of the immune response following adoptive T cell therapy. Similarly, the long-term 
monitoring of adoptively administered stem cells is recognized as a key component in the assess-
ment of therapeutic efficacy in patients undergoing stem cell-based therapies. Ex vivo labeling of 
T-cells or stem cells with MR contrast or radiotracers does not provide an opportunity to monitor 
their long-term trafficking and localization, whereas “genetically labeling” these cells with appropri-
ate reporter systems provides this capability. We and others have demonstrated the feasibility of 
long-term in vivo monitoring of adoptively transferred antigen-specific T cells that were transduced 
(genetically modified) to express a radionuclide-based reporter gene. This provides the opportunity 
to image and track the T cells repeatedly and sequentially over time following the administration of 
a reporter-matched radiolabeled probe.  
“Inducible” promoters respond to endogenous transcription factors and transcription-regulating 
complexes, and can be used as “molecular-genetic sensors”. For example, inducible reporter sys-
tems can monitor T cell activation upon antigen recognition. Since T cell antigen-T cell activation 
results in their proliferation, cytokine secretion and other cytolytic functions, monitoring activated 
T cells at specific target sites is important in the assessment of adoptive T cell efficacy. Inducible 
reporter systems can also be genetically incorporated into stem cells to monitor their differentia-
tion into specific cell types and tissue through the activation of specific signaling pathways during 
differentiation. In addition, specific reporter systems have been constructed to be sensitive-to and 
report-on post-transcriptional processing, modulation of reporter protein translation, protein-protein 
interactions, and reporter protein ubiquitination. Inducible reporter constructs can be used to monitor 
the functional status and characteristics of transduced cells.
Although the initial radionuclide-based reporter systems were developed using viral reporter 
genes (e.g., HSV1-tk), there has been recent interest in developing human reporter genes that avoid 
the potential for initiating an immune response against the reporter-expressing cells. S everal hu-
man genes have been proposed as potential reporter genes for radiotracer-based imaging. These 
genes can be classified into three categories, based on whether the gene product is a receptor, 
a transporter or an enzyme. Examples of highly expressed cell membrane receptors include the spe-
cific membrane somatostatin receptors (hSSTRs). The transporter group includes the sodium-iodide 
symporter (hNIS), and the norepinephrine transporter (hNET). The endogenous enzyme classification 
includes human mitochondrial thymidine kinase 2 (hTK2). One favorable characteristic of this group 
of genes is the availability of radiolabeled probes that have already been approved for clinical gamma 
camera (SPECT) and PET imaging studies. This is largely due to the fact that these radiolabeled 
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probes were developed specifically to image specific tumors (e.g., neuroendocrine tumors), where 
the probes accumulate to high levels due to high expression of a particular receptor or transporter.
The clinical application of PET-based reporter gene imaging will expand over the next several 
years. The translation of reporter gene imaging technology to clinical applications is the focus of 
this presentation, with an emphasis on the development and use of human reporter genes. 
Human reporter genes will play an increasingly more important role in this development and it 
is likely that one or more of the reporter systems (human gene and complimentary radiophar-
maceutical) will take leading roles. 
The initial applications of reporter gene imaging in patients will be developed within two different 
clinical disciplines: a) gene therapy, and b) adoptive cell-based therapies. These studies will 
benefit from the availability of efficient human reporter systems that can provide critical monito-
ring information for adeno-, retro- and lenteviral-based gene therapy, oncolytic bacterial and 
viral therapy, and adoptive cell-based therapies. The translational applications of noninvasive 
in vivo reporter gene imaging are likely to include: (i) quantitative monitoring of the gene therapy 
vector and transduction efficacy in clinical protocols by imaging the location, extent and duration 
of transgene expression; (ii) monitoring cell trafficking, targeting, replication and activation in 
adoptive T cell and stem/progenitor cell therapies; (iii) assessments of endogenous molecular 
events using different inducible reporter gene imaging systems.  
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CARDIAC PET-CT
Juhani Knuuti
Turku PET Centre, University of Turku, Turku, Finland
Abstract
Cardiac PET-CT imaging combines different modalities in order to obtain complementary ana-
tomical and functional information in a single imaging study. Coronary CT angiography (CTA) 
and myocardial perfusion imaging with positron emission tomography (PET) are established 
non-invasive modalities for the diagnosis of coronary artery disease (CAD). Hybrid PET-CT 
is a promising tool for evaluation of CAD allowing detection of the coronary atherosclerotic 
plaques and their consequences on myocardial blood flow in a single study. This appears to 
offer superior diagnostic accuracy for the detection of flow-limiting stenosis in patients with 
intermediate risk for CAD as compared with stand-alone imaging especially by improving the 
positive predictive value.
PET has added an important new dimension to the functional characterization of pathophysio-
logical processes by providing regional information not only on perfusion but also metabolism 
and cell integrity. With the increasing knowledge in molecular biology new imaging targets have 
been identified. Specific receptor families as well as cell surface proteins have been proposeed 
as targets for various imaging approaches using radiolabelled peptides or antibodies. The spe-
cific non-invasive visualisation of protein expression has become possible for diagnosis and 
therapy guidance. Using transgenic approaches, specific proteins can be expressed provi-
ding reporter gene imaging for the visualization of gene expression. These developments are 
believed to be the main players for the success of personalised medicine but also help in drug 
discovery and development.
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PET IN DRUG DEVELOPMENT
Christer Halldin
Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Stockholm, Sweden
The human genome contains over 23.000 genes determining structural and/or functional 
proteins. According to recent estimates, ~4.000 of them can be targeted at ~12.000 var-
ious target sites. Using advanced molecular imaging techniques and molecular imaging 
biomarkers, molecular targets including disease biomarkers and/or disease modifiers can 
be visualized in the living organism. Complemented with animal disease models, with 
special regard to transgenic models, this approach has significant benefits in the field of 
both diagnostic biomarker and therapeutic drug development. Due to the lack of data on 
the functional significance of these sites, pharmacologists are now challenged to find the 
physiological roles of these receptors and identify selective agents and possible therapeutic 
indications. PET provides a new way to image the function of a target from rodents to human 
and by elevating the mass, to pharmacologically modify the function of the target. The main 
applications of radioligands in brain research concern human neuropsychopharmacology 
and the discovery and development of novel drugs to be used in the therapy of psychiatric 
and neurological disorders. A basic problem in PET brain receptor studies is the lack of 
useful radioligands with ideal binding characteristics. During the past decade various 11C- 
and 18F-labeled radioligands have been developed for labeling some of the major central 
neuroreceptor systems. There is still a need to develop pure selective PET tracers for all the 
targets of the human brain. This presentation will review recent examples in neuroreceptor 
radioligand development and PET in drug development. A basic problem in the discovery 
and development of novel drugs to be used in for example the therapy of neurological and 
psychiatric disorders is the absence of relevant in vitro or in vivo animal models that can 
yield results to be extrapolated to man. Drug research and development now benefits from 
the fast development of functional imaging techniques such as translational PET-imaging. 
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PET MONITORING OF HADRONTHERAPY
Katia Parodi
Heidelberg Ion Beam Therapy Centre, Heidelberg, Germany
Department of Radiation Oncology, Heidelberg University Hospital, Germany
The favorable physical properties of ion beam interaction in matter offer the possibility of superior 
tumour-dose conformality with better sparing of surrounding critical organs and healthy tissue in com-
parison to conventional radiation in external beam radiotherapy. However, these advantages come 
at the expense of an increased sensitivity to uncertainties in the dose delivery. In particular, the 
praised finite range of ion beams represents a major source of uncertainty in the patient, hampering 
full clinical exploitation of the ion ballistic properties in the current clinical practice. Although such 
uncertainties can be accounted for via the introduction of cautious safety margins and the avoidance 
of treatment portals directly stopping in front of critical structures, in-vivo and non-invasive validation 
of the actual dose delivery and, in particular, of the ion beam range during the fractionated course 
of radiotherapy would be highly beneficial. 
Over the last years, an increasing interest has been devoted to in-vivo quality assurance of high precision 
ion beam therapy. Although very promising novel concepts have recently been proposed and started 
being investigated, Positron-Emission-Tomography (PET) still offers the only technically feasible method 
for this purpose. The unconventional application of a well-established nuclear medicine imaging moda-
lity to ion therapy monitoring is based on the detection of the transient b+-activation which is induced 
in nuclear interactions between the ions and the irradiated tissue. Depending on the primary ion beam 
species, the mechanism of b+-activation may include either target fragmentation only or the formation of 
both target and projectile positron-emitting fragments. The mechanism of production mainly affects the 
shape of the ion-induced activity and its correlation to the deposited dose. In fact, activated target nuclei 
stay almost at rest in the place of interaction, while positron-emitting projectile fragments travel further and 
accumulate at their end of range. Nevertheless, dose deposition and irradiation-induced activation remain 
different quantitities, due to the underlying electromagnetic and nuclear processes, respectively. Hence, 
treatment verification can be obtained by comparing the actual PET measurement with an expectation 
based on the treatment plan and the time course of irradiation and imaging.
Due to the intrinsically delayed radioactive decay according to the half-lives of the typical reaction 
products (e.g., 10C, 15O, 11C), ranging from few seconds up to several minutes, the PET signal can 
be measured during or shortly after beam delivery. In particular, three major implementations have 
been so far clinically explored, which utilize either dedicated limited angle detectors integrated in the 
beam-delivery (“in-beam”), or commercial full ring scanners located inside (“in-room”) or outside 
(“offline”) the treatment room.
In addition to the technological efforts for efficient use of the very weak (< 10 kBq/Gy/ml) activa-
tion signal induced by the therapeutic irradiation, further challenges of the PET-based verification 
approach include the modeling of the expected PET images including the physiological clearance 
of the produced activity (especially remarkable in offline imaging), the co-registration between the 
imaging and treatment positions (for in-room and offline implementations) as well as the organ 
motion (depending on the anatomical location and the duration of the PET scan).
To date, several examples of clinical implementations of PET-based treatment verification have 
been reported worldwide, exploiting different types of installation to measure the signal induced 
by actively- or passively-shaped ion treatments during or shortly after irradiation. Moreover, several 
investigations have been performed to tackle the challenging problems of in-vivo range monitoring 
and even PET-based dose reconstruction. 
This talk will give an overview of the main examples of clinical implementation, with special focus on 
the own experience in in-beam and offline PET monitoring of carbon ion and proton therapy at the 
GSI Helmholtzzentrum für Schwerionenforschung in Germany, the Massachusetts General Hospital 
in USA, and the Heidelberg Ion Beam Therapy Center in Germany. In particular, it will highlight the 
encouraging clinical results but also the encountered major limitations. Furthermore, it will address the 
most promising developments which are ongoing in order to achieve optimal exploitation of the 
surrogate PET signal for in-vivo quality assurance of high precision ion beam therapy. 
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RADIOTHERAPY TREATMENT PLANNING BASED ON FUNCTIONAL 
PET/CT DATA
Daniela Thorwarth
Section for Biomedical Physics, University Hospital for Radiation Oncology, Eberhard-Karls-University 
Tübingen, Germany
Purpose: To investigate the potential and limitations of functional imaging using combined 
positron emission tomography and computed tomography (PET/CT) for individually adapted 
radiotherapy (RT) treatment planning such as dose painting (DP).
Materials and methods: Functional PET/CT data can be integrated into the RT planning pro-
cess with different levels of complexity. First, metabolic PET information as measured with [18F]-
-fluorodesoxyglucose (FDG) can be used for precise target volume delineation. PET-based target 
volumes may subsequently be used as a basis for intratumoral DP by contours (DPC). Here, different 
algorithms for automatic target volume delineation are investigated: Absolute, relative and automatic 
thresholding, a contrast-oriented algorithm that takes into account the signal-to-background ratio 
(SBR) in the image and finally a gradient based algorithm. In addition to a comparison of the result-
ing target volumes, imaging characteristics originating from different reconstruction methods that 
may be limiting factors for target volume delineation are investigated.
Secondly, molecular information as obtained from hypoxia PET imaging with [18F]-fluoromiso-
nidazole (FMISO) may be used as a basis for locally varying dose adaptation in terms of DP 
by numbers (DP). Here, the requirements for imaging protocols, patient positioning and also 
PET data interpretation and quantification are extremely high. A simulation of FMISO distribu-
tion and accumulation is presented. Furthermore, a compartment model has been developed 
that allows us to extract local hypoxia and perfusion parameters from dynamic FMISO scans. 
Subsequently, a strategy for integrating dynamic FMISO PET/CT information into the RT plan-
ning process in terms of DPN is presented. In addition, the potential of different treatment 
techniques (IMRT, Tomotherapy, Protontherapy) is investigated. 
Results: Functional PET/CT data can be used as basis for individually adapted RT treatment 
planning. A comparison of different automatic delineation algorithms for FDG PET show large 
discrepancies. Additionally, the use of different reconstruction algorithms induces large chan-
ges into the PET characteristics, such as image contrast and maximum standardized uptake 
values (SUV). As a consequence, also PET-based target volume delineation is strongly affected 
by the choice of the reconstruction algorithm. Furthermore, accurate integration of the target 
volumes in the RT planning process is absolutely necessary and requires careful — eventually 
deformable — registration of the functional image data to the planning CT.
To use the local hypoxia information of molecular FMISO PET imaging as a basis for DPN, 
correct and reliable image interpretation is necessary. Local hypoxia and perfusion values are 
extracted from dynamic FMISO PET scans and used as input for hypoxia DPN. DPN and also 
DPC were shown to be technically feasible not only by using dynamic IMRT techniques but also 
with Tomo- and Protontherapy.
Conclusion: Integrating functional PET/CT information into RT planning is feasible, but re-
quires careful handling of patient positioning and image fusion.
Accurate target volume delineation for DPC can be performed on the basis of FDG PET/CT. 
Standardized acquisition and also reconstruction protocols are a prerequisite for PET-based 
PT planning in addition to optimized target volume delineation methods. 
Furthermore, DPN based on e.g. dynamic FMISO PET imaging was shown to be technically 
feasible. Nevertheless, clinical usage of DPN remains unclear due to high biological and also 
geometrical uncertainties. 
However, integration of functional PET/CT data into the RT planning process in terms of therapy 
individualization seems to be highly beneficial and might lead to improved RT outcome in the 
future. 
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FDG PET IN CLINICAL ONCOLOGY
Stefano Fanti
University of Bologna, Bologna, Italy
In recent years molecular imaging is acquiring importance for the evaluation of cancer patients, 
being complementary to conventional imaging methods as CT, MR and US. Among molecular 
imaging procedures, Positron Emission Tomography (PET) is the most diffuse and rapidly 
growing, and at present it is routinely used in patients affected by a large variety of malignant 
neoplastic diseases. Many papers in the literature have already demonstrated the utility of 
this imaging technique whose capabilities have been furthermore developed by the introduction 
of hybrid scanners (PET-CT). The combination of functional data (given by PET) and anatomic 
details (provided by CT) allows to significantly increase diagnostic accuracy, essentially due 
to a better specificity.
The usefulness of PET relies on its capability of investigating molecular processes by means of 
specific radiotracers, with the most employed being 18F-FluoroDeoxyGlucose (FDG). FDG PET 
scans provide important information about tissues glucose consumption, usually very increased 
in the most frequent malignancies as lymphomas, colon carcinoma, lung cancer, breast cancer, 
gynecologic malignancies, gastric cancer, head & neck cancer, testis cancer, oesophageal 
cancer, melanoma and others, covering the great majority of solid malignancies.
Main indications for PET use in clinical oncology are: characterization of uncertain lesions; sta-
ging; early evaluation of response to therapy; evaluation of residual disease at therapy comple-
tion and identification of relapse during follow-up. A typical example of lesion characterization 
is pulmonary solitary nodule. As regards tumor staging, PET ensures an accurate evaluation of 
nodes involvement at disease onset, as the diagnosis of nodes malignancy is based not only 
on size but also on a metabolic index. Furthermore PET is frequently determinant to identify 
metastatic lesions. Malignancies usually undergoing FDG PET for staging includes lung cancer, 
lymphomas, oesophageal cancer, melanoma and others. Evaluation of response to therapy 
is important in many neoplastic affection, such as malignant lymphoma: PET is often the only 
method enabling to document the presence of residual disease after therapy. The use of FDG 
PET to evaluate response to therapy is gaining more and more importance, in order to properly 
plan the treatment on individual basis. Regarding recurrence, PET is particularly important when 
conventional imaging is inconclusive. FDG PET has been demonstrated to be accurate in many 
cancers in case of suspect relapse, for both identifying the site of recurrency and evaluate the 
extent of disease.
Apart from those well established indications, the use of PET is gaining a relevant role in other 
clinically relevant situations, such as radiotherapy planning. Also it is increasing the number of 
disease studied by FDG PET with demonstrated usefulness, as multiple myeloma, bone and 
soft tissue sarcomas and others.
Despite the rapid growth of FDG scans in last decade, we retain PET holds great promises in 
the next few years with the application of other tracers beyond FDG, introduction of PET-MR 
scanners and identification of further clinical application of PET: it is easy to predict that in the 
future PET will continue to increase its impact on clinical and experimental medical science.
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NON-FDG-PET STUDIES IN CLINICAL ONCOLOGY
JN Talbot
Hôpital Tenon AP-HP and Université Pierre et Marie Curie (UPMC), Paris, France
The PET tracer and glucose analogue fluorodeoxyglucose (18F) or FDG has obtained a large 
acceptance in clinical oncology due to its excellent diagnostic performance in many clinical set-
tings (characterisation, staging, radiotherapy planning, therapy follow-up, restaging, detection of 
occult recurrence) of many cancers (lung, colorectal, ENT, lymphoma, melanoma, oesophagus, 
breast, pancreas, ovary, thyroid, testicle…). For a NM department, it is very convenient from the 
logistical point of view to be able to perform PET/CT imaging in so many indications of oncology 
with one single tracer. However, FDG has reduced performance in some cancers, in particular 
the less aggressive and most differentiated ones such as prostate cancer or endocrine tumours, 
and, in one given cancer for some histological types (e.g. pure bronchioloalvear lung cancer or 
mucine-producing digestive or gynaecological cancers) or some localisations (e.g. osteoblastic 
metastases). Furthermore, FDG uptake do not reflect other metabolic/biologic features which 
can be important for the management such as hypoxia, presence of hormone or growth factor 
receptor, induction of apoptosis or damage to DNA.
It is therefore important to validate tracers “beyond FDG”; usually this requires the demonstration 
of superiority over FDG in a precise indication. A routine use of a PET tracer means in practice 
labelling with a radionuclide the half life of which is compatible with production of a batch for 
several patients and delivery, which is possible with 18F but disqualifies 11C. Another possibility 
is a PET radionuclide available on demand by means of a generator, such as 68Ga.
At this moment, three other 18F labelled tracers are registered in several countries of EU, and 
therefore commercially available: FDOPA (18F) for endocrine tumours and brain tumours, fluoride 
(18F) for bone PET/CT, and fluorocholine (18F) or FCH for prostate cancer and hepatocellular 
carcinoma. Others have been documented in series of a significant size and are in the process of 
registration, such as FET for brain cancers or FLT to assess efficacy of radiochemotherapy with 
less dependence to inflammation than FDG. It is to note that those tracers are analogues of small 
molecules, basic constituents of the tissues: carbohydrates, lipids, aminoacids, DNA bases…
Other tracers are not meant to replace FDG in cancers with inconstant FDG uptake but rather to 
complement FDG by addressing specific patterns or properties, such as analogues of oestradiol 
or testosterone for an in vivo detection of the presence of steroid sex hormone receptors in 
metastatic tissue form breast or prostate cancer, or FMISO and other tracers of the same family 
to detect hypoxia, fluorinated-RGD analogues to detect angiogenesis or tracers of apoptotic tissue. 
The small sized metabolic analogues are not the only tracers to be under evaluation. Peptides la-
belled with 68Ga are currently under development, in particular radioligands of receptors which are 
overexpressed in cancer. The most documented example is the family of somatostatin receptors li-
gands such as DOTATOC (68Ga) to detect neuroendocrine tumours, with better performance than 
somatostatin receptor scintigraphy. Ligands of other receptor peptides are entering into preclinical 
or clinical studies. Inhibitors and monoclonal antibodies are developing as therapeutic agents in 
oncology; they are very expensive, with side effects and effective only in some patients. Thus it may 
be worthwhile to label them for PET imaging prior to a therapeutic use to confirm that the therapeutic 
agent concentrates in the target tumours. This paves the way to individually tailored medicine. In 
another approach, the targeting agent is linked to a molecular cage that can chelate radioactive 
metals for diagnostic imaging (68Ga or 64Cu if the binding kinetics is slow) and, if positive, for 
targeted internal radiotherapy with metal radionuclides which are beta — (90Y or 177Lu) or alpha 
emitters (223Ra or 213Bi): the theranostic sequence. 
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PET RECEPTOR IMAGING IN CLINICAL ONCOLOGY
Jolanta Kunikowska, Leszek Królicki
Nuclear Medicine Department, Medical University of Warsaw, Poland
Tumor receptors play an important role in carcinogenesis and tumor growth. The knowledge of 
receptors overexpression such as somatostatin, bombesin, glucagon-like peptide 1, substance 
P, vasoactive intestinal peptides, and cholecystokinin is the way for dedicated diagnosis and 
therapy. 
Neuroendocrine tumors (NET) are a heterogeneous group of carcinomas characterized by 
overexpresion of somatostatin (SSTR) receptors. Indium-111 labeled to the SSTR analogue 
octreotide (Octeroscan) was the first agent to be used and has demonstrated high sensitivity 
in the detection of NETs. Unfortunately, the unfavorable physical properties of 111-In make 
it unsuitable for detecting small tumor lesions leading to false negative results. An attempt 
has been made to introduce somatostatin analogues labeled with 99m-Tc due to the favorable 
physical characteristics of 99m-Tc and better imaging quality; however these are not widely 
available in clinical practice. 
The increased utilization of PET/CT in oncology has led to the introduction of positron emit-
ting tracers labeled to SSTR analogues, of these gallium-68-1,4, 7,10-tetraazacyclododec-
ane-N,N’,N’’,N’’’-tetraacetic acid (gallium-68-DOTA) compounds are the most widely used. 
There are three compounds most often used in functional imaging with PET: 68Ga-DOTATATE, 
68Ga-DOTATOC and 68Ga-DOTANOC. These ligands have different affinity to particular sub-
type of somatostatin receptors, and it may affect their efficiency in the detection of NET lesions. 
68Ga-DOTATATE is a somatostatin analogue that shows high affinity for somatostatin receptor 
subtype 2 (SSTR2) which is the most common subtype found on NET from the GI tract.  The same 
analogue could be labeled with the b(–) emitters like 90Y and 177Lu by the same chelators and 
used in targeted therapy.
In contrast to other NET, insulinomas — neuroendocrine tumours derived from pancreatic 
beta-cells — characterized by relatively low incidence of somatostatin receptor. The sensitivity 
of SRS for detecting insulinomas is only 40–60%. This tumors presented high incidence (> 90%) 
and high density of the glucagon-like peptide 1 receptor (GLP-1R). GLP-1 is rapidly degraded in 
vivo, this is the reason that for clinical use more stable agonist 68 Ga-DOTA-exendin-3 is used. 
Other receptor tracer like gastrin/cholecystokinin-2, bombesin, folate, HER2, neurotensin are 
investigated in animal study. 
